| Dr Mariam Gamal Wassef, DO | |
|
274 Route 35, Eatontown, NJ 07724 | |
| (732) 440-7336 | |
| (732) 440-9404 |
| Full Name | Dr Mariam Gamal Wassef |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 12 Years |
| Location | 274 Route 35, Eatontown, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033475249 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0001X | Internal Medicine - Clinical Cardiac Electrophysiology | 25MB09660600 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jfk Medical Center | Edison, NJ | Hospital |
| Raritan Bay Medical Center Perth Amboy Division | Perth amboy, NJ | Hospital |
| Robert Wood Johnson University Hospital | New brunswick, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hackensack Meridian Health Medical Group - Primary Care Pc | 7911003330 | 273 |
| Barnabas Health Medical Group Pc | 9537316955 | 558 |
News Archive
Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.
The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.
An inter-disciplinary research team led by scientists from the National University of Singapore has successfully employed machine learning to uncover new insights into the cellular architecture of the human brain.
GlaxoSmithKline today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines. Although the committee did not issue any formal recommendations, members widely acknowledged that the benefits of vaccinating infants worldwide against rotavirus disease clearly outweigh the theoretical risks associated with the presence of porcine circovirus type 1 (PCV-1) in the vaccines.
Babies exposed to opioids while their mothers were pregnant with them may need special care even before they start to experience withdrawal symptoms, according to Penn State research.
› Verified 2 days ago
| Entity Name | Barnabas Health Medical Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447206420 PECOS PAC ID: 0648172809 Enrollment ID: O20040127000361 |
News Archive
Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.
The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.
An inter-disciplinary research team led by scientists from the National University of Singapore has successfully employed machine learning to uncover new insights into the cellular architecture of the human brain.
GlaxoSmithKline today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines. Although the committee did not issue any formal recommendations, members widely acknowledged that the benefits of vaccinating infants worldwide against rotavirus disease clearly outweigh the theoretical risks associated with the presence of porcine circovirus type 1 (PCV-1) in the vaccines.
Babies exposed to opioids while their mothers were pregnant with them may need special care even before they start to experience withdrawal symptoms, according to Penn State research.
› Verified 2 days ago
| Entity Name | Hackensack Meridian Health Medical Group - Primary Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336203538 PECOS PAC ID: 7911003330 Enrollment ID: O20070502000000 |
News Archive
Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.
The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.
An inter-disciplinary research team led by scientists from the National University of Singapore has successfully employed machine learning to uncover new insights into the cellular architecture of the human brain.
GlaxoSmithKline today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines. Although the committee did not issue any formal recommendations, members widely acknowledged that the benefits of vaccinating infants worldwide against rotavirus disease clearly outweigh the theoretical risks associated with the presence of porcine circovirus type 1 (PCV-1) in the vaccines.
Babies exposed to opioids while their mothers were pregnant with them may need special care even before they start to experience withdrawal symptoms, according to Penn State research.
› Verified 2 days ago
| Entity Name | Barnabas Health Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841557246 PECOS PAC ID: 9537316955 Enrollment ID: O20120820000951 |
News Archive
Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.
The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.
An inter-disciplinary research team led by scientists from the National University of Singapore has successfully employed machine learning to uncover new insights into the cellular architecture of the human brain.
GlaxoSmithKline today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines. Although the committee did not issue any formal recommendations, members widely acknowledged that the benefits of vaccinating infants worldwide against rotavirus disease clearly outweigh the theoretical risks associated with the presence of porcine circovirus type 1 (PCV-1) in the vaccines.
Babies exposed to opioids while their mothers were pregnant with them may need special care even before they start to experience withdrawal symptoms, according to Penn State research.
› Verified 2 days ago
| Entity Name | Mmc Provider Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932647872 PECOS PAC ID: 9133555626 Enrollment ID: O20200131000598 |
News Archive
Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.
The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.
An inter-disciplinary research team led by scientists from the National University of Singapore has successfully employed machine learning to uncover new insights into the cellular architecture of the human brain.
GlaxoSmithKline today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines. Although the committee did not issue any formal recommendations, members widely acknowledged that the benefits of vaccinating infants worldwide against rotavirus disease clearly outweigh the theoretical risks associated with the presence of porcine circovirus type 1 (PCV-1) in the vaccines.
Babies exposed to opioids while their mothers were pregnant with them may need special care even before they start to experience withdrawal symptoms, according to Penn State research.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mariam Gamal Wassef, DO 74 Brunswick Woods Dr, East Brunswick, NJ 08816-5601 Ph: (732) 947-8084 | Dr Mariam Gamal Wassef, DO 274 Route 35, Eatontown, NJ 07724 Ph: (732) 440-7336 |
News Archive
Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.
The advantages of prescribing angiotensin-converting enzyme (ACE) inhibitors for stable coronary artery disease (CAD) may be increased by targeting the therapy to the patients most likely to benefit.Clinical characteristics alone do not allow a reliable identification of these patients, so a research programme was carried out at Erasmus University Medical Centre in Rotterdam to develop a genetic profiling model that predicts the treatment benefits of ACE inhibitors and optimises the recommended therapy.
An inter-disciplinary research team led by scientists from the National University of Singapore has successfully employed machine learning to uncover new insights into the cellular architecture of the human brain.
GlaxoSmithKline today participated in a U.S. Food and Drug Administration (FDA) advisory committee meeting convened to discuss recent findings of porcine circovirus (PCV) in rotavirus vaccines. Although the committee did not issue any formal recommendations, members widely acknowledged that the benefits of vaccinating infants worldwide against rotavirus disease clearly outweigh the theoretical risks associated with the presence of porcine circovirus type 1 (PCV-1) in the vaccines.
Babies exposed to opioids while their mothers were pregnant with them may need special care even before they start to experience withdrawal symptoms, according to Penn State research.
› Verified 2 days ago
Violet Elizabeth Kramer, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 30 Corbett Way, Eatontown, NJ 07724 Phone: 732-380-0020 | |
Hank Ashforth, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 145 Wyckoff Rd Ste 301, Eatontown, NJ 07724 Phone: 848-208-5250 | |
Dr. Bharath Sathya, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Meridian Rd, Eatontown, NJ 07724 Phone: 732-663-0300 Fax: 732-663-0301 | |
Dr. Jeffrey Osofsky, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Meridian Rd, Eatontown, NJ 07724 Phone: 732-663-0300 Fax: 732-663-0301 | |
Dr. Charles Mattina, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 11 Meridian Rd, Eatontown, NJ 07724 Phone: 732-663-0300 Fax: 732-663-0301 | |
Jason David Litsky, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 11 Meridian Rd, Eatontown, NJ 07724 Phone: 732-663-0300 Fax: 732-663-0301 |